The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis , a league source told Reuters on Thursday.

Entresto, approved in heart failure since 2015, has long been one of Novartis’ top growth drivers, bringing home $4.05 billion in U.S. sales in 2024. That said, a key combination patent on the ...

EAST HANOVER, N.J. - Novartis, a global leader in innovative medicines with a market capitalization of $217 billion and an impressive "GREAT" financial health rating according to InvestingPro ...

Novartis’s (NVS) parasite-selective proteasome inhibitor with potent activity against kinetoplastid parasites was granted FDA orphan designation for treatment of leishmaniasis, according to a ...

Novartis (NVS) announced positive safety and efficacy results from the Phase III program for investigational intrathecal onasemnogene abeparvovec, OAV101 IT, in a broad population of patients aged ...

EAST HANOVER, N.J. - Novartis, a global leader in innovative medicines with a market capitalization of $217 billion and an impressive "GREAT" financial health rating according to InvestingPro, has ...

TOKYO (Reuters) -Swiss pharmaceutical giant Novartis (SIX:NOVN) will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early April, Chief Executive ...

The affirmative regulatory decision is the third for Novartis’s Fabhalta, building up the drug’s pipeline-in-a-product potential. But competition looms from a rival drug taking a similar approach.

By Paul Arnold and Maggie Fick ZURICH (Reuters) -Swiss drugmaker Novartis is ending its use of diverse panels for all of its ...

EAST HANOVER, N.J. - Novartis (Market Cap: $223.4B), a pharmaceutical giant with robust financial health according to InvestingPro metrics, has announced the FDA approval of Fabhalta (iptacopan) for ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

A judge in the US has denied an attempt by Novartis to stop MSN Pharmaceuticals from launching a generic version of heart failure blockbuster Entresto. MSN Pharma was given FDA approval for its ...